Hikma launches AdriamycinTM (DOXOrubicin HCl) for Injection, USP


Hikma launches AdriamycinTM (DOXOrubicin HCl) for Injection, USP

London, 17 September 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces that Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp., has launched AdriamycinTM (DOXOrubicin HCl) for Injection, USP 10mg and 50mg.

Hikma’s AdriamycinTM (DOXOrubicin HCl) for Injection, USP is an anthracycline topoisomerase II inhibitor indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. Additionally, Doxorubicin is indicated for the treatment of certain other cancers: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma.

According to IQVIA, US sales of doxorubicin HCl were approximately $13 million in the 12 months ending July 2018. Sales of doxorubicin HCl 10mg and 50mg currently comprise approximately 15 per cent of the market.

This new product introduction expands Hikma’s broad offering of more than 90 products and further solidifies our position as one of the top three suppliers of generic injectable products to US hospitals.